QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

22,437 signal articles · 89 in last 24h · 107,740 total before filter · latest 41m ago
89last 24h
2559last 7d
493● bullish (7d)
237● bearish (7d)
201publishers
AllMacro215Earnings1595M&A123Regulatory16Product10Analyst25
✕ clear all filtersSentiment:bullishneutralbearishshow all (incl. clickbait)
Private credit roundup: Earnings hold up as defaults, redemptions remain elevated
Reuters8d agoneutral
Private credit roundup: Earnings hold up as defaults, redemptions remain elevated

Ares Capital and Blue Owl Capital reported resilient second-quarter results this week, while Ares Management posted record fundraising, highlighting continued institutional demand for private credit despite rising defaults, ‌retail redemptions and liquidity concerns. Ares Management, one of the industry's largest players, raised a record $36 billion ‌in the second quarter, including $23.7 billion for its credit strategies. Assets under management rose 17% from a year earlier to $671.3 billion.

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.
Barrons.com8d agobullish
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.

AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.

KKR & Co. Inc. Q2 Earnings Call Highlights
MarketBeat8d agoneutral
KKR & Co. Inc. Q2 Earnings Call Highlights

KKR & Co. Inc. (NYSE:KKR) reported record second-quarter results for 2026, led by growth in management fees, fundraising, capital deployment and monetization activity across its asset management, insurance and strategic holdings businesses. Fee-related earnings were $1.32 per share, up 34% from a y

Jones Lang LaSalle Q2 Earnings Call Highlights
MarketBeat8d agoneutral
Jones Lang LaSalle Q2 Earnings Call Highlights

Jones Lang LaSalle (NYSE:JLL) reported second-quarter 2026 revenue growth of 11% in U.S. dollars and 10% in local currency, supported by broad strength in its advisory operations and continued growth in recurring-service businesses. Adjusted EBITDA rose 33% and adjusted earnings per share increased

KBR Q2 Earnings Call Highlights
MarketBeat8d agoneutral
KBR Q2 Earnings Call Highlights

KBR (NYSE:KBR) reported second-quarter 2026 revenue of approximately $2 billion, up 2% from the prior-year period, while adjusted EBITDA rose $16 million to $258 million and adjusted EPS increased $0.08 to $0.99. The company said first-half results were tracking slightly ahead of its planned cadence

Kinross Gold Q2 Earnings Call Highlights
MarketBeat8d agoneutral
Kinross Gold Q2 Earnings Call Highlights

Kinross Gold (NYSE:KGC) reported second-quarter production of 492,000 gold equivalent ounces and attributable free cash flow of $727 million, as the company said it remains on track to meet its 2026 production, cost and capital-spending guidance. Chief Executive Officer Paul Rollinson said the comp

Cameco (CCJ) Q2 Earnings Miss Estimates
Zacks8d agobearish
Cameco (CCJ) Q2 Earnings Miss Estimates

Cameco (CCJ) delivered earnings and revenue surprises of -50.00% and +10.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?
Barrons.com8d agobullish
Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?

Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.